Journal Information
Vol. 92. Issue 5.
Pages 539-540 (September - October 2016)
Vol. 92. Issue 5.
Pages 539-540 (September - October 2016)
Letter to the Editor
Open Access
Atypical manifestations of Epstein-Barr virus: red alert for primary immunodeficiencies
Manifestações atípicas do vírus de Epstein-Barr: alerta vermelho para imunodeficiências primárias
Visits
3180
Gesmar R.S. Segundo
Universidade Federal de Uberlândia (UFU), Departamento de Pediatria, Uberlândia, MG, Brazil
Related content
J Pediatr (Rio J). 2016;92:113-2110.1016/j.jped.2015.06.007
Vasileios Bolis, Christos Karadedos, Ioannis Chiotis, Nikolaos Chaliasos, Sophia Tsabouri
Vasileios Bolis, Christos Karadedos, Ioannis Chiotis, Nikolaos Chaliasos, Sophia Tsabouri
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor,

The Jornal de Pediatria has published an elegant review paper entitled “Atypical manifestations of Epstein-Barr virus in children: a diagnostic challenge”.1 The authors performed a literature review including the last 30 years of publications on atypical manifestations associated with an Epstein-Barr virus (EBV) infection. However, I would like to complement their review by providing a particularly important point of view related to atypical EBV infections.

EBV is a gamma-1 herpes virus restricted to primate hosts, characterized by its persistence in the B-lymphoid system, and its capacity to stimulate B-cells growth by coordinating the expression of latent cycle genes.2 Most EBV-infected individuals are asymptomatic or present infectious mononucleosis syndrome with a benign course, especially teenagers and young adults.2,3 In its normal course, EBV infects B-cells and the immune system controls the virus using a complex mechanism that involves NK, iNKT, CD4, and CD8 cells. Genetic alterations leading to functional NK or T-cell impairment may lead to a failure in the EBV control mechanisms.3

Primary immunodeficiencies (PIDs) are a group of different diseases that cause alterations in the development and/or function of the immune system, leading to an increased susceptibility to infections and, in some cases, increased incidence of autoimmune diseases and malignancies. Most PID cases are genetic diseases that follow simple Mendelian patterns of inheritance, while a few others are considered as complex disorders.4,5 The advance in the genetic approaches in the last years has increased the pace at which causative genes for PIDs are being discovered.5

Recently, Palendira and Rickson, in a educational and simple method, divided PID patients into groups to explain the susceptibility to EBV infections: (1) PIDs that are selectively susceptible to EBV; (2) PIDs with broader virus susceptibility, but frequent EBV disease; (3) PIDs generally susceptible to viral and nonviral infections; and (4) PIDs with an inherent susceptibility to lymphoma.2

Group 1 includes the X-linked lymphoproliferative diseases type 1, caused by SH2D1A gene mutations, and type 2, associated with XIAP gene mutations. In both diseases, patients could present severe infectious mononucleosis; and acute disease could result in a cytokine storm that causes macrophage activation and hemophagocytic lymphohistiocytosis (HLH).2,4 In another review, authors added three different PIDs to this group, including mutations in the genes PRF1 (perforin deficiency, autosomal recessive (AR)), STXBP2 (munc18-2 deficiency, AR), and UNC13D (munc13-4 deficiency, AR), which are also associated with HLH and the development of chronic and severe EBV disease.6

Group 2 contains PIDs caused by mutations in genes CD27 (CD27 deficiency, AR), MAGT1 (XMEN syndrome, X-linked), ITK (ITK deficiency, AR), CORO1A (coronin-1A deficiency, AR), FCGR3 (CD16 deficiency, AR), and MCM4 (MCM4 deficiency, AR).2 The diseases in this group showed an increased susceptibility not only to EBV, but also to other herpes virus family and, in some cases, to HPV.4

Group 3 has complex PIDs with different predispositions to several microorganisms, including EBV infections. The PIDs included in this group are result of mutations in genes PIK3CD (Activated PI3-kinase delta syndrome, autosomal dominant (AD)), STK4 (MST1 deficiency, AR), ZAP70 (Zap-70 deficiency, AR), CTPS1 (CTPS1 deficiency, AR), CARD11 (CARD11 deficiency, AR), LRBA (LRBA deficiency, AR), GATA2 (mono MAC syndrome or GATA2 deficiency, AD), LYST (Chediak-Higashi syndrome, AR), and hypomorphic mutations in ARTEMIS and DNA ligase IV, both associated with Omenn syndrome.2,4,6

The PIDs in group 4 present different degrees of immune system deficiency, which are also associated with increased cancer incidence and the involvement of EBV in some of these tumors, especially lymphomas. This group includes PIDs with mutations in genes WAS (Wiskott–Aldrich syndrome, X-linked), ATM (Ataxia telangiectasia syndrome, AR), and TNFRSF6 (ALPS-FAS, AD and AR).2,4,6

The message for all pediatricians is to consider EBV as a causative agent in clinical pictures similar to those described by Bolis et al. In addition to the immune system impairment associated with treatment for several diseases, we must also consider these situations as a red alert for primary immunodeficiencies in pediatric patients. Recognizing PIDs may be essential to achieve a better management for patients with atypical EBV infections.

Funding

C.H.I.L.D.R.E.N. initiative for primary immunodeficiency research of the Jeffrey Modell Foundation; Postdoctoral Fellow abroad through Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES (Higher Education Personnel Improvement Coordination).

Conflicts of interest

The author declares no conflicts of interest.

References
[1]
V. Bolis, C. Karadedos, I. Chiotis, N. Chaliasos, S. Tsabouri.
Atypical manifestations of Epstein-Barr virus in children: a diagnostic challenge.
J Pediatr (Rio J), 92 (2016), pp. 113-121
[2]
U. Palendira, A.B. Rickinson.
Primary immunodeficiencies and the control of Epstein-Barr virus infection.
Ann NY Acad Sci, 1356 (2015), pp. 22-44
[3]
D.J. Moss, V.P. Lutzky.
EBV-specific immune response: early research and personal reminiscences.
Curr Top Microbiol Immunol, 390 (2015), pp. 23-42
[4]
C. Picard, W. Al-Herz, A. Bousfiha, J.L. Casanova, T. Chatila, M.E. Conley, et al.
Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015.
J Clin Immunol, 35 (2015), pp. 696-726
[5]
N. Fodil, D. Langlais, P. Gros.
Primary immunodeficiencies and inflammatory disease: a growing genetic intersection.
Trends Immunol, 37 (2016), pp. 126-140
[6]
J.I. Cohen.
Primary immunodeficiencies associated with EBV disease.
Curr Top Microbiol Immunol, 390 (2015), pp. 241-265

Please cite this article as: Segundo GR. Atypical manifestations of Epstein-Barr virus: red alert for primary immunodeficiencies. J Pediatr (Rio J). 2016;92:539–40.

Copyright © 2016. Sociedade Brasileira de Pediatria
Download PDF
Idiomas
Jornal de Pediatria (English Edition)
Article options
Tools
en pt
Taxa de publicaçao Publication fee
Os artigos submetidos a partir de 1º de setembro de 2018, que forem aceitos para publicação no Jornal de Pediatria, estarão sujeitos a uma taxa para que tenham sua publicação garantida. O artigo aceito somente será publicado após a comprovação do pagamento da taxa de publicação. Ao submeterem o manuscrito a este jornal, os autores concordam com esses termos. A submissão dos manuscritos continua gratuita. Para mais informações, contate assessoria@jped.com.br. Articles submitted as of September 1, 2018, which are accepted for publication in the Jornal de Pediatria, will be subject to a fee to have their publication guaranteed. The accepted article will only be published after proof of the publication fee payment. By submitting the manuscript to this journal, the authors agree to these terms. Manuscript submission remains free of charge. For more information, contact assessoria@jped.com.br.
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.